Genentech-Lodo sign agreement for soil-based drug discovery
Category: #health  By Pankaj Singh  Date: 2018-05-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech-Lodo sign agreement for soil-based drug discovery

Genentech, a Roche subsidiary, has reportedly signed a deal with Lodo Therapeutics for around $1 billion to employ the genome mining technology of Lodo for a new drug discovery. The deal seems to be a first for Lodo which has a backing of $17 million from Accelerator Life Science Partners.

If reports are to be believed, the alliance includes an upfront amount that has not been disclosed and commercial and research and development milestone payments of $969 million. In the event that the products reach the market, tiered royalties would be provided on sales, as per a clause included in the deal. The disease categories that will be pursued through the alliance have not yet been disclosed.

Sources state that natural products have been the starting point for various drugs – similar to how microorganisms and plants have been the origins of various drugs like aspirin, derived from willow bark. As per estimates, in the last few decades, around three quarters of cancer drugs and medicines to treat chronic diseases like type 2 diabetes have been derived from natural sources. Authentic reports suggest that the increased focus of pharmaceutical companies on large-molecule drugs and synthetic small-molecules drugs based on combinatorial chemistry has slowed down the investment in naturally sourced drugs. However, this collaboration seemingly points toward the renewal of interest in naturally sourced medicines.

In partnership with Genentech, Lodo will search for naturally-occurring small molecules from microbial DNA that exhibit therapeutic potential. The process of drug discovery can be slow and depends largely on chance. Lodo Therapeutics claims to be able to speed up the process with its genome-based approach that also helps in lowering the costs of finding compounds for drug resistant bacterial infections and cancer.

Reliable sources quoted co-founder of Lodo Therapeutics, David Pompliano, saying that the strategic collaboration of Lodo Therapeutics with one of the leaders of innovative drug technology clearly highlights the potential of the proprietary platform that Lodo represents and its value to advanced drug discovery initiatives.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...